Companies › Aravax
1 active drug program in 1 registered trial: 1 Phase 2; Immunology; next expected readout Jun 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PVX-108 Peptide immunotherapy containing peanut allergen-derived peptides | – | Phase 2 | Peanut Allergy | Jun 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05621317 | PVX-108 | Phase 2 | Peanut Allergy | Immunology | Jun 2028 |
No annotated target.
–
VivaTech International AltruBio Qu Biologics 4Moving Biotech Bluefin Biomedicine
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.